deltatrials
Terminated PHASE1/PHASE2 INTERVENTIONAL 2-arm NCT03652259

Gene Delivery Clinical Trial of SRP-9003 (Bidridistrogene Xeboparvovec) for Participants With Limb-Girdle Muscular Dystrophy, Type 2E (LGMD2E) (Beta-Sarcoglycan Deficiency)

A Single-Center, Open-Label, Systemic Gene Delivery Study to Evaluate the Safety, Tolerability, and Efficacy of SRP-9003 Administered by Systemic Infusion in Subjects With LGMD2E (β-Sarcoglycan Deficiency)

Sponsor: Sarepta Therapeutics, Inc.

Conditions Limb-Girdle Muscular Dystrophy, Type 2E
Interventions SRP-9003
Updated 19 times since 2018 Last updated: Jan 12, 2026 Started: Oct 27, 2018 Primary completion: Jan 14, 2025 Completion: Jan 14, 2025
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Study is being terminated due to a business decision.

Other terminated trials from Sarepta Therapeutics, Inc.

More terminations from Sarepta Therapeutics, Inc.

Listed as NCT03652259, this PHASE1/PHASE2 trial focuses on Limb-Girdle Muscular Dystrophy, Type 2E and remains terminated or withdrawn. Sponsored by Sarepta Therapeutics, Inc., it has been updated 19 times since 2018, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

~Sep 2018 – ~Oct 2018 · 30 days · monthly snapshot~Oct 2018 – ~Nov 2018 · 31 days · monthly snapshot~Nov 2018 – ~Jan 2019 · 2 months · monthly snapshot~Jan 2019 – ~Feb 2019 · 31 days · monthly snapshot~Feb 2019 – ~Sep 2019 · 7 months · monthly snapshot~Sep 2019 – ~Nov 2019 · 2 months · monthly snapshot~Nov 2019 – ~Mar 2020 · 4 months · monthly snapshot~Mar 2020 – ~Apr 2020 · 31 days · monthly snapshot~Apr 2020 – ~Nov 2020 · 7 months · monthly snapshot~Nov 2020 – ~Jan 2021 · 2 months · monthly snapshot~Jan 2021 – ~Sep 2021 · 8 months · monthly snapshot~Sep 2021 – ~Oct 2022 · 13 months · monthly snapshot~Oct 2022 – ~Mar 2024 · 17 months · monthly snapshot~Mar 2024 – ~Jul 2024 · 4 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~May 2025 · 8 months · monthly snapshot~May 2025 – ~Oct 2025 · 5 months · monthly snapshot~Oct 2025 – ~Feb 2026 · 4 months · monthly snapshot~Feb 2026 – present · 5 months · monthly snapshot

Change History

19 versions recorded

  1. Feb 2026 — Present [monthly]

    Terminated PHASE1/PHASE2

  2. Oct 2025 — Feb 2026 [monthly]

    Terminated PHASE1/PHASE2

    Status: Active Not Recruiting → Terminated

  3. May 2025 — Oct 2025 [monthly]

    Active Not Recruiting PHASE1/PHASE2

  4. Sep 2024 — May 2025 [monthly]

    Active Not Recruiting PHASE1/PHASE2

  5. Jul 2024 — Sep 2024 [monthly]

    Active Not Recruiting PHASE1/PHASE2

    Phase: PHASE1_PHASE2 → PHASE1/PHASE2

▶ Show 14 earlier versions

  1. Mar 2024 — Jul 2024 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  2. Oct 2022 — Mar 2024 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  3. Sep 2021 — Oct 2022 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  4. Jan 2021 — Sep 2021 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  5. Nov 2020 — Jan 2021 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  6. Apr 2020 — Nov 2020 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  7. Mar 2020 — Apr 2020 [monthly]

    Active Not Recruiting PHASE1_PHASE2

    Status: Recruiting → Active Not Recruiting

  8. Nov 2019 — Mar 2020 [monthly]

    Recruiting PHASE1_PHASE2

  9. Sep 2019 — Nov 2019 [monthly]

    Recruiting PHASE1_PHASE2

  10. Feb 2019 — Sep 2019 [monthly]

    Recruiting PHASE1_PHASE2

  11. Jan 2019 — Feb 2019 [monthly]

    Recruiting PHASE1_PHASE2

  12. Nov 2018 — Jan 2019 [monthly]

    Recruiting PHASE1_PHASE2

  13. Oct 2018 — Nov 2018 [monthly]

    Recruiting PHASE1_PHASE2

  14. Sep 2018 — Oct 2018 [monthly]

    Recruiting PHASE1_PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Sarepta Therapeutics, Inc.
Data source: Sarepta Therapeutics, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations